里昂发表研究报告指出，华润医药(03320.HK) 中期收入按年增长2%，净利润按年增长5.3%，大致符合市场预期。期内毛利率及经营利润率分别下跌0.3及0.4个百分点，主要受分销业务利润率受压的影响。制药业务销售按年跌1.5%，受到天士力整合贡献减弱、流感相关产品销售下跌及血液制品业务销售减少拖累，部分被原料药(API)销售增长2.7%及营养保健品销售增长17.6%所抵销。基于中期业绩表现，里昂...
Source Link里昂发表研究报告指出，华润医药(03320.HK) 中期收入按年增长2%，净利润按年增长5.3%，大致符合市场预期。期内毛利率及经营利润率分别下跌0.3及0.4个百分点，主要受分销业务利润率受压的影响。制药业务销售按年跌1.5%，受到天士力整合贡献减弱、流感相关产品销售下跌及血液制品业务销售减少拖累，部分被原料药(API)销售增长2.7%及营养保健品销售增长17.6%所抵销。基于中期业绩表现，里昂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.